Trial
NCT01551693
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Synta Pharmaceuticals Corp.
Condition
Melanoma
Intervention
STA-9090
Why stopped
due to weak accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-12